Tempus AI Faces Lawsuit for Disclosure of Genetic Data
Tempus AI is facing class action lawsuits associated with the unlawful collection and disclosure of genetic data obtained through its acquisition of Ambry Genetics and subsequent use of that data in artificial intelligence model development and third-party agreements.
Case Background
Healthcare artificial intelligence company, Tempus AI, acquired Ambry Genetics Corporation in February 2025 for $600 million. As part of that transaction, Ambry Genetics shared its database of genetic information to Tempus AI. The database included the data of thousands of individuals.with Tempus AI. T
Ambry Genetics provides genetic testing services for screening and diagnosing inherited and non-inherited diseases. Allegedly, HIPAA-covered entity Tempus AI used the genetic data for the development and training of artificial intelligence models.
Tempus AI faced multiple class action lawsuits for collecting and disclosing genetic data without proper authorization. On April 15, 2026, the lawsuits were combined into the Farrier et al v. Tempus AI, Inc. case and filed in the U.S. District Court for the Northern District of Illinois.
The complaint alleges that Tempus AI compelled Ambry Genetics to transfer genetic data obtained through its testing services and then disclosed that data to third-party partners. The plaintiffs claim that these actions violated the Illinois Genetic Information Privacy Act and additional state statutes.
The litigation states that Tempus AI shared the genetic data with more than 70 partner companies. These companies include pharmaceutical firms such as GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca, and Pfizer, as well as biotechnology firms including Aspera Biomedicines, Incyte, Servier, and Whitehawk Therapeutics.
Tempus AI had $1.1 billion in revenue through its agreements involving the disclosed genetic data.
Claims Related to De-Identification
Tempus AI reports maintaining a clinical and molecular data library consisting of 45 million de-identified patient records. This dataset includes 8.5 million clinical records, 2 million medical images, and 1 million matched clinical-genomic data.
The plaintiffs claim that Ambry Genetics and Tempus AI only disclosed de-identified genetic information. The complaint asserts that genetic information cannot be de-identified because it functions as an inherently unique biometric identifier. The allegations state that the nature of genetic data makes it inherently identifiable, regardless of de-identification claims.
Legal Claims and Jurisdictions
The consolidated complaint includes 21 counts. These claims include negligence, fraudulent concealment, unjust enrichment, conversion, breach of implied contract, breach of contract, breach of fiduciary duty, and invasion of privacy under intrusion upon seclusion.
Additional claims involve violations of consumer protection and data protection laws, as well as deceptive trade practices statutes across multiple states. The states identified in the complaint include California, Florida, Georgia, Illinois, Michigan, New York, and West Virginia.
Requested Relief
The plaintiffs are seeking a jury trial. The requested remedies include monetary damages, injunctive relief, and other relief determined by the court. The complaint also seeks a court order requiring Tempus AI to stop sharing genetic data unless individuals are first provided with proper notice and written consent is obtained.